URGN

NEUTRALAnalyst

UroGen Pharma Ltd.

2026-07-28

Price

$40.88

-1.40%

This is the 2026-07-28 snapshot — the signals and analysis for URGN as of this single trading day.

View full URGN research hub →

Score1.0Noise

Signals2/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.5xvs 20d avg

Analysis

URGN is demonstrating High-Conviction Price Discovery, driven by upward analyst estimate revisions and a critical US patent allowance extending protection for its bladder cancer treatments to 2044. These fundamental catalysts perfectly align with bullish technical signals, notably a PERFECT_STACK and GOLDEN_CROSS, confirming strong institutional accumulation. While the broader CAUTION (EARNINGS) macro regime brings tech-heavy turbulence, exceptionally tight credit spreads provide a highly supportive backdrop for idiosyncratic biotech growth stories like URGN to detach from broader market anxieties.

Fired Signals

GOLDEN CROSSPERFECT STACK

Key Takeaways

Actionable Thesis: URGN offers a high-conviction idiosyncratic long setup, backed by upward analyst revisions, robust technicals, and recent IP protection extensions to 2044 [1.2.7].
Key Risk: The stock's high annualized volatility (44.4%) leaves it vulnerable to sudden pullbacks if upcoming Q2 earnings fail to meet the market's newly elevated expectations.
What to Watch: Monitor price action around the $36.80 support level (20-day closing low) and the upcoming Q2 earnings release in early August to confirm ongoing commercial traction.

← Back to 2026-07-28 View Full URGN History →Yahoo Finance &nearr;